<DOC>
	<DOCNO>NCT01839487</DOCNO>
	<brief_summary>To compare treatment effect PEGPH20 combine nab-paclitaxel gemcitabine ( PAG ) nab-paclitaxel gemcitabine ( AG ) subject Stage IV pancreatic cancer . The Phase 2 study safety treatment effect 237 subject ( 2:1 randomization , PAG : AG ) , precede two run-in phase ( first ass safety tolerability second assess new formulation PEGHP20 ) , 16 subject total ( randomized 3:1 ) .</brief_summary>
	<brief_title>PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine Subjects With Stage IV Untreated Pancreatic Cancer</brief_title>
	<detailed_description>1 . Phase 2 , multicenter open-label randomize study two run-in phase . The first run-in phase evaluate safety tolerability PEGPH20 + Nab-paclitaxel + Gemcitabine vs. Nab-paclitaxel + Gemcitabine . A second run-in phase evaluate new formulation PEGPH20 . Phase 2 open-label randomize study study drug evaluate safety efficacy . 2 . Subjects must newly diagnose stage 4 untreated metastatic pancreatic ductal cancer diagnose standard Care CT scan within 20 day dose meet inclusion/exclusion criterion . 3 . Treatment consist 4 week treatment cycle Week 4 every cycle , wash-out week . In Cycle 1 , PEGPH20 administer twice per week Nab-paclitaxel + Gemcitabine give once/week 2-4 hr PEGPH20 nab-paclitaxel + gemcitabine alone 4 . Safety parameter include medical history , physical exam , adverse event Concomitant med collection , Doppler CT scan thromboembolic event , prophylactic enoxaparin , Karnofsky Performance scale , Immunogenicity , Hematology , Chemistry , coagulation , Weight/body surface area ( BSA ) dosing , ECG pharmacokinetics ( PK ) Hyaluronan ( HA ) catabolite level . Efficacy parameter include standard care CT scan , CA19-9 , tumor analysis HA . 5 . Subjects continue study disease progression , adverse event/toxicity , death either subject/sponsor discontinues study .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Key Signed Informed consent Histologically confirm Stage IV pancreatic ductal adenocarcinoma w/ document disseminated neoplasm liver /or lung . Must archival fresh tissue ( block /slides ) available predose . One measurable metastatic tumor measurable CT san per Response Evaluation Criteria Solid Tumors ( RECIST v.1.1 ) , exclude primary lesion . No previous radiotherapy , surgery , chemotherapy investigational therapy treatment metastatic disease . Karnofsky Performance Status &gt; = 70 % Life expectancy &gt; = 3 mo Age &gt; = 18 year Screen labs Hemoglobin , platelet , absolute neutrophil count ( ANC ) , bilirubin , AST , ALT , serum creatinine , serum albumin , PT/INR , PTT within specify values/criteria per protocol prior dose . Key Non metastatic pancreatic ductal adenocarcinoma Evidence deep vein thrombosis ( DVT ) pulmonary embolism ( PE ) know thromboembolic event present screening period . Known Central nervous system involvement , brain metastasis New York ( NY ) Heart Association Class III IV cardiac disease Myocardial infarction within past 12 month . Prior history cerebrovascular accident transient ischemic attack Preexisting carotid artery disease Active , uncontrolled bacterial , viral fungal infection require systemic therapy . Current use megestrol acetate ( Use within 10 day Day 1 ) Known infection human immunodeficiency virus , Hepatitis B , Hepatitis C History another primary cancer within last 3 year exception nonmelanoma skin cancer , early state prostate cancer , curativelytreated cervical cancer insitu . Contraindication heparin per NCCN guideline Previous major bleed ( bleed require transfusion red blood cell ) LMWH Any disease , metabolic dysfunction , physical examination find clinical lab find lead reasonable suspicion disease condition contraindicate use investigational drug , may affect interpretation result , render subject high risk treatment complication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>pancreatic ductal carcinoma ( PDA )</keyword>
	<keyword>Pancreatic ductal carcinoma</keyword>
	<keyword>PEGPH20</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Nab-paclitaxel</keyword>
</DOC>